For example, aberrant DDR activation has been linked to resistance in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), with FLT3-ITD and Bcr-Abl mutations conferring resistance to tyrosine kinase inhibitors (TKIs) such as imatinib (Huang and Zhou, 2021). Here, FLT3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.